medigraphic.com
ISSN 0035-0052 (Impreso)

2001, Número 5

<< Anterior Siguiente >>

Rev Mex Pediatr 2001; 68 (5)


Efecto del clofibrato, asociado a fototerapia sobre la concentración de bilirrubina en niños recién nacidos

Caballero-Noguéz B, Hernández PS, Rodríguez BJE, Quiróz MM, Flores CI

Idioma: Español
Referencias bibliográficas: 34
Paginas: 176-180
Archivo PDF: 49.61 Kb.


RESUMEN

Objetivo. Probar la efectividad del clofibrato para tratar neonatos con hiperbilirrubinemia indirecta no hemolítica.
Material y métodos. Se seleccionaron 30 recién nacidos dentro de la primera semana de vida extrauterina, que tenían hiperbilirrubinemia indirecta no hemolítica. Se formaron al azar tres grupos constituidos de la siguiente manera: grupo I (n = 9) al cual se le administró fenobarbital; grupo II (n = l2) con clofibrato; grupo III, (n = 9) que recibió placebo. Los grupos recibieron fototerapia. Se les midió la bilirrubina total y la indirecta al inicio del estudio y a las 24, 48 y 72 horas.
Resultados. El grupo con clofibrato y el que recibió fenobarbital mostraron una significancia estadística con una p ‹ 0.05 y p ‹ 0.01, respectivamente, a las 48 y 72 horas, con respecto al grupo que recibió el placebo. Los grupos I y II no mostraron diferencias significativas durante el tiempo que duró el estudio.
Conclusiones. El clofibrato mostró ser un inductor enzimático tan bueno como el fenobarbital, sin los efectos de tipo sedativo de este último medicamento. No se observaron efectos secundarios atribuibles a su empleo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Rammer H, Merker HJ. Drug induced changes in the liver endoplasmic reticulum. Association with drug metabolizing enzymes. Science 1963; 142: 1657.

  2. Conney AH. Pharmacological implication of microsomal enzyme induction. Pharmacol Rev 1967; 19: 317-19.

  3. Blaschke TF, Berk PD, Rodkey FL. Drugs and the liver, effects of glutethimide and phenobarbital on hepatic bilirubin clearance, plasma bilirubin turnover and carbon monoxide production in man. Biochem Pharmacol 1974; 23: 2795-99.

  4. Black M, Sherlock S. Treatment of Gilbert’s syndrome whit phenobarbitone. Lancet 1970; 1: 1359-63.

  5. Hunter J, Thompsom RPH, Rake MO. Controlled trial of phenobarbital a nonhypnotic barbiturate in conjugated hyperbilirubinemia. Br Med J 1971; 1: 497-99.

  6. Gabilan JC, Benattar C, Lindenbaum A. Clofibrate treatment of neonatal jaundice. Lettter to editor. Pediatrics 1990; 86: 648-9.

  7. Kappas A, Drummond GS, Manola T. The use of Sn-Protopor phyrin in the management of hiperbilirubinemia in newborn infants with direct Coombs positive ABO-incompatibility. Pediatrics 1988; 81: 485-87.

  8. Odell GB, Gutcher GR, Whitington PF. Enteral administration of agar as an effective adjunt to phototerapy of neonatal hyperbilirubinemia. Pediatr Res 1983; 17: 810-14.

  9. Windorfer A, Kunzer W, Bolze H. Studies on the effect of orally administered agar on the serum bilirubin level of premature infants and mature newborns. Acta Paediatr Scand 1975; 64: 699-702.

  10. Moller J. Agar ingestion and bilirubin values in newborn infant. Acta Obstet Scand 1974; 53: 61-3.

  11. Ebbesen F, Moller J. Agar ingestion combined with phototerapy in jaundiced newborn infants. Biol Neonate 1977; 31: 7-9.

  12. Poland RL, Odell GB. Physiologic jaundice: the enterohepatic circulation of bilirubin. N Engl J Med 1971; 284: 1-6.

  13. Maurer HM, Wolff JA, Glinster M, Poppess PJ, Pantrick E, Kuntzman R et al. Reduction in concentration of total serum bilirubin in offspring of women treated with phenobarbitone during pregnancy. Lancet 1968; 2: 122-4.

  14. Valaes T, Kipouros K, Petmezaki S, Solman M, Doxiadis SA. Effectiveness and safety of prenatal phenobarbital for the prevention of neonatal jaundice. Pediatr Res 1980; 14: 947-52.

  15. Trolle D. Decrease of total serum-bilirubin concentration in newborn infants after phenobarbital treatment. Lancet 1968; 2: 705-8.

  16. Salle B, Pasquer P, Desebbe CI, Rouzioux JM, Barouty B. Phenobarbital in prophylaxis of neonatal jaundice. Helv Paediatr Acta 1977; 32: 221-6.

  17. Royer RJ, Vert P, Mur JM, Pladys JC, Humbert F, Royer-Morrot MJ. Données pharmacocinétiques sur le phénobarbital. Etude de l’influence de l’áge gestationnel et de la dysmaturité. Arch Fr Pediatr 1976; 33: 905-13.

  18. Wallin A, Jalling B, Boreus LO. Plasma concentration of phenobarbital in the neonate during prophylaxis for neonatal hyperbilirubinemia. J Pediatr 1974; 85: 135-9.

  19. Stern L, Khanna NN, Levy G, Yaffe SJ. Effect of phenobarbital on hyperbilirubinemia and glucoronide formation in newborns. Am J Dis Child 1970; 120: 26-31.

  20. Cunningham MD, Mace JW, Peters ER. Clinical experience with phenobarbitone in icterus neonatorum. Lancet 1969; 1: 550-1.

  21. Levin GE, McMullin GP, Mobarak AN. Controlled trial of phenobarbitone in neonatal jaundice. Arch Dis Child 1970; 45: 93-5.

  22. Ramboer C, Thompson RPH, Williams R. Controlled trials of phenobarbitone therapy in neonatal jaundice. Lancet 1969; 1: 966-8.

  23. Foliot A, Drocourt JL, Etienne JP, Housset E, Fiessinger JN, Christoforov B. Increase in the glucuronidation and clearance of bilirubin in clofibrate treated rats. Biochem Pharmacol 1977; 26: 547-9.

  24. Jean F, Foliot A, Celier C, Housset E. Influence du clofibrate sur le transport hépatique de la bilirubine et de la excretion sulfonephtatéine chez le rat. Biol Gastroenterol 1976; 9: 342-3.

  25. Roberts RJ, Plaa GL. Effect of phenobarbital on the excretion of an exogenous bilirubin load. Biochem Pharmacol 1967; 18: 827-35.

  26. Kutz K, Loffler A, Kaudler H, Fevery J. Clofibrate: a potent serum bilirubin lowering agent in subjects with Gilbert’s syndrome. Digestion 1975; 12: 255.

  27. Lindenbaum A, Hernandorena K, Vial M, Benattar C, Janaud M, Dehan M et al. Traitement curatif de l’ictère du nouveau-ne’ à terme par le clofibrate. Essai thérapeutique contrôle en double aveugle. Arch Fr Pediatr 1981; 38: 867-73.

  28. Lindenbaum A, Delaporte B, Benattar C, Dehan M, Magny JF, Gerbet D et al. Traitement préventif de l’ictère du nouveau-ne’ prématuré par le clofibrate. Essai thérapeutique contrôle en double aveugle. Arch Fr Pediatr 1985; 42: 759-63.

  29. Hunter J, Thompsom RPH, Rake MO. Controlled trial of phenobarbital a nonhypnotic barbiturate in conjugated hyperbilirubinemia. Br Med J 1971; 1: 497-99.

  30. Anwar M, Valdivieso J, Hiatt IM, Hegyi T. The course of hyperbilirubinemia in the very low birth weight infant treated with phenobarbital. J Perinatal 1987; 2: 145-8.

  31. Black M, Fevery J, Parker D. Effect of phenobarbitone on plasma C-bilirubin clearance in patients with unconjugated hyperbilirubinemia. Clin Scin Med 1974; 46: 1-4.

  32. Roberts RJ, Plaa GL. Effect of phenobarbital on the excretion of an exogenous bilirubin load. Biochem Pharmacol 1967; 16: 827-30.

  33. Blackburn MG, Orzalesi MM, Pigram P. The combined effect of phototherapy and phenobarbital on serum bilirubin levels of premature infants. Pediatrics 1972; 49: 110-13.

  34. Valdes OS, Maurer HM, Shumway CN. Controlled clinical trial of phenobarbital and/or ligth in reducing neonatal hyperbilirubinemia in a predominantly niger population. J Pediat 1971; 79: 1015-18.




2020     |     www.medigraphic.com